These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23139210)

  • 1. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.
    McCleland ML; Adler AS; Shang Y; Hunsaker T; Truong T; Peterson D; Torres E; Li L; Haley B; Stephan JP; Belvin M; Hatzivassiliou G; Blackwood EM; Corson L; Evangelista M; Zha J; Firestein R
    Cancer Res; 2012 Nov; 72(22):5812-23. PubMed ID: 23139210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
    Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
    Schubert A; Hawighorst T; Emons G; Gründker C
    Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond triple-negative breast cancer: the need to define new subtypes.
    Constantinidou A; Jones RL; Reis-Filho JS
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1197-213. PubMed ID: 20735307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.
    Collins LC; Marotti JD; Gelber S; Cole K; Ruddy K; Kereakoglow S; Brachtel EF; Schapira L; Come SE; Winer EP; Partridge AH
    Breast Cancer Res Treat; 2012 Feb; 131(3):1061-6. PubMed ID: 22080245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.
    Tuomela J; Sandholm J; Karihtala P; Ilvesaro J; Vuopala KS; Kauppila JH; Kauppila S; Chen D; Pressey C; Härkönen P; Harris KW; Graves D; Auvinen PK; Soini Y; Jukkola-Vuorinen A; Selander KS
    Breast Cancer Res Treat; 2012 Sep; 135(2):481-93. PubMed ID: 22847512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is triple-negative breast cancer?
    Irvin WJ; Carey LA
    Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular stratification of triple-negative breast cancers.
    Perou CM
    Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.
    Walsh S; Flanagan L; Quinn C; Evoy D; McDermott EW; Pierce A; Duffy MJ
    Breast; 2012 Apr; 21(2):178-82. PubMed ID: 21963359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
    Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
    Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.